Revenio Group Oyj - Interim report (Q1 and Q3)

Revenio Group Corporation: Interim Report January 1 - September 30, 2016

Revenio Group Corporation, Stock Exchange Release, October 31, 2016 at 9:00 am

Interim Report January 1-September 30, 2016

Due to an amendment to the Securities Market Act, which came into force on
November 26, 2015, the descriptive sections of Revenio's interim reports Q1/2016
and Q1-Q3/2016 will be shorter and more concise than before. The table sections
will be reported in accordance with previous practices. The figures are
unaudited.

Revenio Group Corporation has adopted the publication procedure enabled by the
Financial Supervisory Authority's Regulations and guidelines 7/2013 (Disclosure
obligation on issuers) and is publishing its Interim Report for January-
September 2016 as an appendix to this stock exchange release. This release is a
summary of Revenio Group Corporation's Interim Report January-September 2016,
which is available in full in the pdf file attached to this stock exchange
release, and on the company website at www.revenio.fi.


Third quarter operating profit grew strongly by 17.6%

July-September 2016 in brief, continuing Group operations

  * Net sales totaled EUR 5.8 (5.3) million, showing an increase of 8.7 per
    cent.
  * Operating profit was EUR 1.9 (1.6) million, up by 17.6 per cent
  * Strong growth in probe sales continued, amounting to EUR 1.7 (1.4) million,
    or 29.3 per cent of net sales
  * An application has been filed for a CE marking for the asthma product to be
    named Ventica
  * Factors contributing to operating profit growth included probe production
    process enhancement and a reduction in other operating costs
  * Earnings per share, undiluted EUR 0.20 (0.17)

January-September 2016 in brief, continuing Group operations

  * Net sales amounted to EUR 16.8 (14.8) million, up by 13.6 per cent from the
    previous year
  * Operating profit was EUR 4.9 (4.5 million), an increase of 8.6 per cent
  * Earnings per share, undiluted EUR 0.49 (0.47)
  * Sales permit for Icare ic100 granted in the United States
  * Revenio will have a new CEO as of January 1, 2017

Key figures, continuing operations, EUR million:

           1.7-30.9.2016 1.7-30.9.2015 Change 1.1-30.9.2016 1.1-30.9.2015 Change
                                           -%                                 -%

 Net
 sales,              5.8           5.3    8.7          16.8          14.8   13.6
 Group

 Operating
 profit,             1.9           1.6   17.6           4.9           4.5    8.6
 Group

 Net
 sales,              5.8           5.3    8.7          16.8          14.8   13.6
 Health
 Tech

 Operating
 profit,             2.3           2.0   17.8           6.1           5.6    8.1
 Health
 Tech

 Undiluted
 earnings           0.20          0.17   17.6          0.49          0.47    4.3
 per share

 Cash flow
 from
 operating                                              4.0           3.5   13.4
 activ-
 ities

                                                30 Sep 2016   30 Sep 2015 Change
                                                                          %point

 Equity                                                78.9          83.0   -4.1
 ratio-%

 Gearing-%                                            -36.4         -44.2    7.8



Financial guidance for 2016

Net sales growth is expected to remain strong. Profitability is expected to
remain at a healthy level despite growth investments.


Olli-Pekka Salovaara, President & CEO, comments on third quarter of 2016:

"During the period, Icare tonometer sales developed well in countries with
significant growth potential, such as China, Canada and Russia. The United
States remains our single largest market and our customers' positive reactions
towards our new products create positive expectations for the future.

During the review period the probe production process enhancements were
completed thus having a positive impact on the strong operative profit.
Furthermore, in the absence of the sales permit, no costs have incurred in
relation to the Icare HOME tonometer launch in the United States.

Sales of the Icare ic100 tonometer, launched in Europe at the beginning of the
year, had a good start. The Icare ic100 was granted a sales permit in the United
States in April, and the product launch is currently under way.

Feasibility studies of the Icare HOME tonometer have been completed, and we
expect to file a sales permit application with the FDA by the year-end, as
planned.

Development projects involving skin cancer and asthma-related products are
moving forward as planned.

The sales growth on third quarter was not what we expected, but I believe that
the fourth quarter of the year will be stronger what comes to sales."


General statement

This report contains certain statements that are estimates based on the
management's best knowledge at the time they were made. For this reason, they
involve a certain amount of inherent risk and uncertainty. The estimates may
change in the event of significant changes in general economic conditions.

Revenio Group Corporation
Board of Directors

For further information, please contact:
Olli-Pekka Salovaara, President & CEO, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on a strongly patented intraocular pressure
measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio
Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The
common denominators of Revenio's business operations include screening, follow-
up and the global need to make cost savings through preventive health care.
Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's screening
technology is on the early detection of glaucoma, osteoporosis, skin cancer and
asthma, and the monitoring of these during the treatment process.

In 2015, Revenio Group's net sales totaled MEUR 20.3, with its operating margin
for continuing operations standing at 28.4%. Revenio Group Corporation is listed
on Nasdaq Helsinki.




[]

Attachments:

Revenio Group Corporation Interim Report Q3 2016.pdf